**Supplemental Digital Content 2a.** Patient characteristics of infants exposed to anti-TNFα during pregnancy.

|  |  |  |  |
| --- | --- | --- | --- |
|  | All anti TNF α n  | Adalimumab n | Infliximab n |
| gestational age at birth in weeks#prematurity\* | 38.3 (27- 41.9) 406 (15%) | 37.3 (27-40.3) 104 (40%) | 38.7 (29.9-41.9) 302 (7%) |
| birth weight in grams#SGA\* | 3070 (1060-4200) 395 (12%) | 3042 (1100-3778) 100 | 3070 (1060-4200) 295 (17%) 29 |
| Male\* | 13 (33%) | 1 (10%) | 12 (40%) |
| gestational age at last use anti-TNF α# | 32.0 (20-38) 33 | 26.1 (16.9-39) 7 | 27.7 (16.9-39) 26 |
| Interval use anti-TNF α and birth in weeks# | 10.7 (0-22.9) 33 | 4.4 (2.3- 15.1) 7 | 11.0 (0 –22.9) 26 |
| Concentration anti TNF α (μg/ml) * Birth
* Age 3 months
* Age 5 months
* Age 12 months
 |  6.50 (0.029-39.00) 340.65 (0-6.50) 280.10 (0-1.40) 240.11 (0-0.29) 10 | 4.40 (0.2-14.0 90.20 (0.06-2.20) 50.01 (0.01-0.03) 40.19 1 | 7.10 (0.029-39.00) 250.70 (0.00-6.50) 230.15 (0.00-1.40) 200.029 (0-0.29) 9 |
| other immunosuppressive medication besides anti TNF α\** Azathioprine
* Azathioprine+ mesalazine
* Thioguanine
* Mercaptopurine
* Mesalazine
* Dexamethason
* Beclomethasone
 |  409 (23%)1 (3%)1 (3%)6 (15%)3 (8%)1 (3%)1 (3%) |  102 (20%)----1(10%)- |  307 (23%)1 (3%)1 (3%)6 (20%)3 (10%)1 (3%) |

Anti-TNFα= anti-Tumor necrosis Factor α; #;median with range \*;number and percentage of children; SGA= small for gestational age with birth weight <p3

**Supplemental Digital Content 2B.** Anti-TNF α (ADA= adalimumab, IFX= infliximab) use during pregnancy and concentration of anti TNF α in cord blood

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Case  | Type of anti TNF α | Dose (mg)  | Dose interval (weeks) | Gestational age last use anti-TNF α# | Interval anti-TNF α and birth in weeks | Concentration anti-TNFα at birth (μg/ml) |
| 1 | ADA  | 40  | 2 | 38 | 2.3 | 14.0 |
| 2 | ADA  | 40  | 1 | 32 | 4.4 | 3.0 |
| 3 | ADA  | 40  | 1 | 36 | 2.3 | 5.4 |
| 4 | ADA  | 40  | 2 | 31.9 | 5.6 | 4.4 |
| 5 | IFX  | 300  | 8 | 27.9 | 10.3 | 14.0 |
| 6 | IFX | 300  | 6 | 30.3 | 8.4 | 8.6 |
| 7 | IFX | 300  | 8 | 26.6 | 11.0 | 0.03 |
| 8 | IFX | 400  | 6 | 25.4 | 11.4 | 6.70 |
| 9 | IFX | 300  | 6 | 17.1 | 22.9 | 0.03 |
| 10 | IFX | 400  | 8 | 16.9 | 21.4 | 0.20 |
| 11 | IFX | 450  | 6  | 26.1 | 13.0 | 2.60 |
| 12 | IFX | 300 | 8  | 26 | 12.3 | 6.30 |
| 13 | IFX | 500 | 6 | 27.7 | 13.7 | 4.40 |
| 14 | IFX | 300 | 8 | 28.3 | 10.4 | 9.5 |
| 15 | IFX | 600 | 4 | 24 | 5.9 | 14.0 |
| 16 | IFX | 400 | UN | 32.3 | 8.0 | 11.0 |
| 17 | IFX | 400 | 6 | 26 | 11.0 | 15.0 |
| 18 | IFX | 300 | 8 | 28.4 | 10.7 | 9.0 |
| 19 | IFX | 400 | 8 | 32.6 | 5.1 | 7.0 |